Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

v2.4.1.9
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Operating expenses:    
Research and development $ 321,439us-gaap_ResearchAndDevelopmentExpense $ 217,868us-gaap_ResearchAndDevelopmentExpense
General and administrative 782,846us-gaap_GeneralAndAdministrativeExpense 656,216us-gaap_GeneralAndAdministrativeExpense
Total operating expenses 1,104,285us-gaap_OperatingExpenses 874,084us-gaap_OperatingExpenses
Other income (expense), net:    
Research & development tax credit 0eyeg_ResearchAndDevelopmentTaxCredit 2,940eyeg_ResearchAndDevelopmentTaxCredit
Interest income 164us-gaap_InvestmentIncomeInterest 307us-gaap_InvestmentIncomeInterest
Interest expense (1,920,146)us-gaap_InterestExpense (32,055)us-gaap_InterestExpense
Change in warrant liability 223,172us-gaap_FairValueAdjustmentOfWarrants 0us-gaap_FairValueAdjustmentOfWarrants
Other income (expense), net 10us-gaap_OtherNonoperatingIncomeExpense 0us-gaap_OtherNonoperatingIncomeExpense
Total other expense, net (1,696,801)us-gaap_NonoperatingIncomeExpense (28,808)us-gaap_NonoperatingIncomeExpense
Net Loss (2,801,086)us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple (902,892)us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple
Deemed dividend on preferred stock (8,222,008)us-gaap_PreferredStockDividendsAndOtherAdjustments 0us-gaap_PreferredStockDividendsAndOtherAdjustments
Net income attributable to non-controlling interests (5,177)us-gaap_NetIncomeLossAttributableToNoncontrollingInterest (58,948)us-gaap_NetIncomeLossAttributableToNoncontrollingInterest
Net (loss) attributable to Eyegate Pharmaceuticals, Inc. stockholders (11,028,271)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic (961,840)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Net loss per common share - basic and diluted $ (3.23)us-gaap_EarningsPerShareBasicAndDiluted $ (0.47)us-gaap_EarningsPerShareBasicAndDiluted
Weighted average shares outstanding - basic and diluted 3,417,509us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 2,025,527us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted
Net loss (2,801,086)us-gaap_ProfitLoss (902,892)us-gaap_ProfitLoss
Other comprehensive income (loss):    
Foreign currency translation adjustments 51,325us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax 8,994us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
Comprehensive income (loss) (2,749,761)us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest (911,886)us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
Less:    
Net income attributable to non-controlling interests (5,177)us-gaap_NetIncomeLossAttributableToNoncontrollingInterest (58,948)us-gaap_NetIncomeLossAttributableToNoncontrollingInterest
Other comprehensive (income) loss attributable to non-controlling interests 32,967us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest (6,819)us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
Comprehensive income attributable to non-controlling interests 27,790us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest (65,767)us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
Comprehensive loss attributable to Eyegate Pharmaceuticals, Inc. stockholders $ (2,721,971)us-gaap_ComprehensiveIncomeNetOfTax $ (959,665)us-gaap_ComprehensiveIncomeNetOfTax